Business
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update
- Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion - Planning to present
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"- Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion\n - Planning to present data at AACR in April 2021 for IDE397 (monotherapy efficacy in over forty PDX models with homozygous MTAP deletions across tumor types) and for PARG (monotherapy efficacy in CDX and PDX models based on defined biomarker)\n - Hosting inaugural IDEAYA Synthetic Lethality Investor Day April 20, 2021 at 1:00 pm ET\n - Targeting Development Candidates for PARG and Pol Theta programs in 2021\n - Initiated dose expansion in the Phase 1/2 study of IDE196 / binimetinib combination in metastatic uveal melanoma (MUM) based on early clinical activity\n - Targeting interim data for IDE196 / binimetinib combination in MUM and for IDE196 monotherapy in MUM and GNAQ/11-mutation skin melanoma in 2021, including tolerability, clinical efficacy, and survival data for IDE196 monotherapy\n\n\nSOUTH SAN FRANCISCO, Calif., March 23, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the fourth quarter ended December 31, 2020.\n\n \n \n \n \n \n \n\n \n\"In the last quarter, we have made important progress towards our goal to build a preeminent synthetic lethality-focused precision medicine oncology company, including advancing IDE397 into Phase 1 as a potential best-in-class MAT2A inhibitor to treat patients with MTAP-deletion, which represents approximately 15% of all solid tumors. We are also poised to expand our synthetic lethality pipeline, targeting Development Candidate nominations in 2021 for each of our potential first-in-class PARG and Pol Theta programs. Lastly, IDE196 has reached a key inflection point as we initiated dose expansion in our Phase 1/2 study evaluating the IDE196 / binimetinib combination in the GNAQ/11 mutation-driven cancer of metastatic uveal melanoma,\" said Yujiro S. Hata, Chief Executive Officer and President of IDEAYA Biosciences. \nProgram UpdatesKey highlights for IDEAYA's pipeline programs include: \nIDE397 (MAT2A)IDEAYA is developing IDE397, a potent and selective small molecule inhibitor targeting methionine adenosyltransferase 2a (MAT2A), for solid tumor...